Oncology Medical News about C-Raf

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas
Clinical Cancer Research, 09/15/09

Jilaveanu LB et al. – C–Raf siRNA knock–down results in decreased viability of YULAC (B–RafV600K) and YUROB (B–RafWT) melanoma cells, likely mediated by Bcl–2 inhibition rather than mitogen–activated protein kinase inhibition. Cotargeting C–Raf and parallel pathways might be an effective therapeutic approach for melanoma. C–Raf expression is up–regulated in a subset of melanomas but not in nevi, suggesting that it might be a valuable diagnostic marker and therapeutic target.

<< Previous
Clinicopathological study on peripheral T-cell non-Hodgkin...

Next >>
Decreased Poly(ADP-Ribosyl)ation of CTCF, a Transcription Factor,...